Early trials of angiogenic factors have not targeted patients most at risk of ocular diseaseBMJ 1999; 319 doi: https://doi.org/10.1136/bmj.319.7210.643c (Published 04 September 1999) Cite this as: BMJ 1999;319:643
- Martin McKibbin, specialist registrar in ophthalmologya,
- Damian O'Neill, consultant ophthalmologist
- Eye Clinic, Leeds General Infirmary, Leeds LS2 9NS
EDITOR—In his clinical review on therapeutic angiogenesis Henry discusses the potential benefits of this treatment in relation to myocardial and limb ischaemia.1 Vascular endothelial growth factor, fibroblast growth factor, and the angiopoietin receptors have already been evaluated in disease models and small clinical trials and shown to be beneficial. The use of these agents highlights a paradox of subspecialty medicine.
Henry briefly mentions the danger of pathological angiogenesis in other tissues, and this is of particular relevance …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial